A new study led by researchers at WashU Medicine suggests that younger generations are aging biologically faster than their older counterparts. This faster biological aging was also linked to early-onset cancers.

The Cardiovascular Research Foundation^® (CRF^®) will present the New York Valves Career Achievement Award to Igor F. Palacios, MD, honoring his pioneering advances in structural heart intervention and his enduring influence on cardiovascular medicine through innovation, research, and mentorship. Dr. Palacios will receive the award during New York Valves: The Structural Heart Summit^® to be held June 24–26, 2026 at the Jacob K. Javits Convention Center, North.

Genital herpes is a lifelong infection. While available treatments can manage symptoms, they cannot cure the infection or prevent transmission. Now, Yale School of Medicine researchers have taken a significant step toward a genital herpes vaccine that in preclinical models prevented infection.

In a study published June 19 in Science Immunology, researchers evaluated a two-part vaccination against genital herpes. With the technique, the first part — a typical intramuscular injection like you would receive for a flu shot, for example — is followed by the introduction of nanoparticles to the vagina, where herpes infection occurs in women.

The idea is the initial injection “primes” the immune system while the second localized treatment “pulls” immune activity right to where infection takes place. This study extends the original “prime and pull” approach by developing a new nanoparticle that effectively induces local immunity.

Researchers at the Icahn School of Medicine at Mount Sinai have found that wearable devices may help clinicians detect cytokine release syndrome (CRS)—a common and potentially serious side effect of CAR-T cell therapy—hours earlier than standard hospital monitoring in patients with multiple myeloma, a blood cancer that begins in plasma cells in the bone marrow.